Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | QPCT | Q16769 | 1/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6190954 | 1.00 | HDAC4 (0.36) | HDAC4HDAC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6192794 | 0.96 | NPC1 (0.36) | HDAC4HDAC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25224563 | 0.78 | FOLH1 (0.34) | SMN1; SMN2SIRT5EPHX1MEN1KMT2A | |
| SCHEMBL20358313 | 0.78 | FOLH1 (0.34) | SMN1; SMN2SIRT5EPHX1MEN1KMT2A | |
| SCHEMBL6209427 | 0.77 | MEN1 (0.40) | HDAC4HDAC1NPC1RAB9AQPCT | |
| SCHEMBL6209428 | 0.77 | MEN1 (0.40) | HDAC4HDAC1NPC1RAB9AQPCT | |
| SCHEMBL4811672 | 0.76 | MEN1 (0.50) | SIRT5MEN1KMT2AGAA | |
| SCHEMBL6211331 | 0.75 | MEN1 (0.52) | HDAC4HDAC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6747808 | 0.75 | FOLH1 (0.52) | NPC1RAB9ASMN1; SMN2FOLH1 | |
| SCHEMBL18063326 | 0.73 | MEN1 (0.33) | MEN1KMT2AGAAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299365-A1 | 2-AMINOTHIAZOLINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | Aventis Pharma S.A. (FR) | 2003-04-09 | — | — | EP | disclosed |
| US-6451821-B1 | ADMINISTERING TO A PATIENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF 2-AMINOTHIAZOLINE DERIVATIVES FOR TREATING OR PREVENTING DISEASE CONDITIONS ASSOCIATED WITH AN ABNORMAL PRODUCTION OF NITRIC OXIDE(NO) | AVENTIS PHARMA S.A. (FR) | 2002-09-17 | — | — | US | disclosed |
| WO-2001094325-A1 | 2-AMINOTHIAZOLINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2001-12-13 | — | — | WO | disclosed |